Clinical significance of broad-spectrum β-lactamases and experience with their identification in microbiological practice;Klinický význam širokospektrých β-laktamáz a zkušenosti s jejich identifikací v mikrobiologické praxi

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 13, Issue 5, 2007, Pages 195-205

  Kolář, Milan ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Bacterial lactamases; Clinical importance; Detection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPA; BETA LACTAMASE AMPC; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; COLISTIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENOMIC DNA; IMIPENEM; MEROPENEM; NITROFURANTOIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; CLINICAL PRACTICE; DNA DETERMINATION; ENZYME ANALYSIS; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; NONHUMAN; PHENOTYPE; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; MICROBIAL SENSITIVITY TESTS;

EID: 38049082231     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Livermore DM, Paterson DL. Pocket guide to extended spectrum β-lactamases in resistance. Spain: Current Medicine Group Ltd; 2006.
2. Ghuysen JM. Serine β-lactamases and penicillin-binding proteins. Ann Rev Microbiol. 1991;45:37-67.
3. Datta N, Kontomichalou P. Pbnicillinase synthesis controlled by infectious R factors in Enterobactenaceae. Nature. 1965;208:239-244.
4. Medeiros AA. β-lactamases. Br Med Bull. 1984;40:18-27.
5. Barthelemy M, Peduzzi J, Labia R. Distinction entre les structures primaires des β-lactamases TEM-1 et TEM-2. Ann Inst Pastear Microbiol. 1985;136(A):311-321.
6. Bradford PA. Extended-spectrum-β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Mcrobiol Rev. 2001;14:933-951.
7. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother. 1985;28:302-307.
8. Queenan AM, Foleno B, Gownley C, Wra E, Bush K. Effects of inoculum, and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol. 2004;42:269-275.
9. Thomson KS, Sanders CC. Detection of extended-spectrum β-lactamases in members of the family Enterobactariaceae: comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother. 1992;36:1877-1882.
10. Kolář M, Látal T, Čermák P, et al. Prevalence ESBL-pozitivních kmenů Klebsiella pneumoniae v České republice a jejich molckulárně-biologická analýza. Klin Mikrob Inf Lék. 2005;11:92-99.
11. Bauernfeind A, Casellas JM, Goldberg M, et al. A new plasmidic cefotaxime from patients infected with Salmonella typhimurium. Infection. 1992;20:158-163.
12. Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM. Sequences of β-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other β-lactamases. Antimicrob Agents Chemother. 1996;40:509-513.
13. Ambler RP. The structure of β-lactamases. Phil Trans R Soc Lond Biol Sc. 1980;289:321-331.
14. Bush K, Jacoby G, Medeiros A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-1233.
15. Liu PYF, Tung JC, Ke SC, Chen SL. Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a district hospital in Taiwan. J Clin Microbiol. 1998;36:2759-2762.
16. Weller TM, MacKenzie FM, Forbes KJ. Molecular epidemiology of a large outbreak of multiresistant Klebsiella pneumoniae. J Med Microbiol. 1997;46:921-926.
17. Yu WL, Winokur PL, Jones RN, Sader HS. Surveillance in Taiwan using molecular epidemiology for extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Inf Control Hosp Epidemiol. 2004; 25:812-818.
18. Gori A, Espinasse F, Deplano A. Comparison of pulsed-field gel electrophoresis and randomly amplified DNA polymorphisin analysis for typing extended-spectrum-β-lactamase-producing Klebsiella pneumoniae. J Clin Microbiol. 1996;34:2448-2453.
19. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119:353-358.
20. Bauernfeind A, Chong Y, Schweighart S. Extended broad-spectrum β-lactamase in Klebsiella pneumoniae including resistence to cephamycins. Infection. 1989;17:316-321.
21. Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated β-lactamase (MIR-1) conferring resistance to oxyimino- and α-medioxy β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1990;34:2200-2209.
22. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella sp. from intensive care units in Europe. J Antimicrob Chemother. 1996;38:409-424.
23. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents. 2006;27:476-481.
24. N H, Kang CI, Byeon JH, et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004; 48:3720-3728.
25. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988;10:867-878.
26. Tzelepi E, Giakkoupi P, Sofianou D, et al. Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol. 2000,38:542-546.
27. Pitout JDD, Reisbig MD, Venter EC, Church DL, Hanson ND. Modification of the double-disk test for detection of Enterobacteriaceae producing extended-spectrum and AmpC β-lactamases. J Clin Microbiol. 2003;41:3933-3935.
28. Essack SY. Laboratory detection of extended-spectrum β-lactamases (ESBLs) - the need for a reliable, reproducible method. Diagn Microbiol Inf Dis. 2000;37:293-295.
29. Thomson KS, Sanders CC. Detection of extended-spectniin β-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother. 1992;36:1877-1882.
30. Performance standards for antimicrobial susceptibility testing, seventeenth informational supplement. M100-S17. CLSI;2007.
31. Hrabák J, Vaniš V, Bergerová T, Urbášková P. Průkaz β-laktamáz širokého spektra (ESBL) a typu AmpC u enterobakterií. Zprávy CEM. 2007;16:31-36.
32. Kesselová M, Kolář M, Sauer P, et al. Molekulárně-biologická analýza ESBL-pozitivních kmenů Klebsiella pneumoniae na novorozeneckém oddélení Fakultní nemocnice Olomouc. Klin Mikrob Inf Lék. 2005;11:20-24.
33. Bauernfeind A, Stemplinger I, Jungwirth R, Giamarellou H. Characterization of the plasmidic β-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob Agents Chemother. 1996;40:221-224.
34. Pfaller MA, Jones RN, Marshall SA, et al. Inducible AmpC β-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Inf Dis. 1997;28:211-219.
35. Dunne WM, Hardin DJ. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol. 2005;43:5945-5949.
36. Moland ES, Hanson ND, Black JA, et al. Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Mcrobiol. 2006; 44:3318-3324.
37. Philippon A, Arlet G, Jacoby GA Plasmid-deterinined AmpC-type beta-lactamases. Antimicrob Agents Chemother. 2002;46:1-11.
38. Condron PE. Inhibitor-based methods for detection of plasmid-mediated AmpC β-lactamases in Klebsiella spp., Escheiichia coli, and Proteus mirabilis. J Clin Microbiol. 2005; 43:4163-4167.
39. Yagi T, Wachino J, Kurokawa H, et al. Practical methods using boronic acid compounds for identification of class C β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 2005;43:2551-2558.
40. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC beta-lactamases among Eschenchia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a Veterans Medical Center. J Clin Microbiol. 2000;38:1791-1796.
41. Black JA, Moland ES, Tbomson KS. AmpC disk test for detection of plasmid-mediated AmpC β-lactamases in Enterobactariaceae lacking chromosomal AmpC β-lactamases. J Clin Microbiol. 2005;43:3110-3113.
42. Manchanda V, Singh NP. Occurrence and detection of AmpC β-lactamases among gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur hospital, Delhi, India. J Antimicrob Chemother. 2003;51:415-418.
43. Nasim K, Elsayed S, Pilout JDD, et al. New method for laboratory detection of AmpC β-lactamases in Escherichis coli and Klebsiella pneumoniae. J Clin Microbiol. 2004;42:4799-4802.
44. Paterson DL, Hujer KM, Hujer AM, et al. Extended spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother. 2003; 47:3354-3560.